<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35122289</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2559</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Histopathology</Title>
          <ISOAbbreviation>Histopathology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CDX2 expression in malignant peripheral nerve sheath tumour: a potential diagnostic pitfall associated with PRC2 inactivation.</ArticleTitle>
        <Pagination>
          <StartPage>995</StartPage>
          <EndPage>1000</EndPage>
          <MedlinePgn>995-1000</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/his.14626</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Malignant peripheral nerve sheath tumour (MPNST) is a soft tissue sarcoma that exhibits features of Schwann cell differentiation. Heterologous, often mesenchymal-type differentiation occurs in a subset of MPNST, while glandular morphology also is encountered in rare cases. We observed in MPNST unanticipated expression of CDX2, a transcription factor that regulates intestinal epithelial differentiation, and aimed to further characterize this phenomenon.</AbstractText>
          <AbstractText Label="METHODS/RESULTS" NlmCategory="RESULTS">Expression of CDX2 was assessed by immunohistochemistry in a total of 32 high-grade MPNSTs lacking morphological evidence of epithelial differentiation, including twelve tumours (38%) that developed in the setting of neurofibromatosis and four (13%) in the setting of prior radiation therapy. CDX2 was expressed by 14 of 32 MPNSTs (44%), wherein immunoreactivity, varying from weak to strong, was present in 2-95% of neoplastic spindle cells (median 10%, mean 23%). Notably, CDX2 expression was limited to tumours with PRC2 inactivation (22/32; 69%), as evidenced immunohistochemically by diffuse loss of trimethylated histone H3K27. Analysing publicly available RNA-sequencing data from twelve MPNST cell lines, two of which are clonally related, we observed CDX2 expression in all six PRC2-inactivated cell lines, while CDX2 expression was negligible in six cell lines with intact PRC2, amounting to a 58-fold increase in CDX2 expression on average with PRC2 inactivation.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CDX2 is expressed in a subset of MPNSTs, even in the absence of morphological evidence of epithelial differentiation. CDX2 expression in MPNST is strongly associated with underlying PRC2 inactivation.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Odeyemi</LastName>
            <ForeName>Olumide O</ForeName>
            <Initials>OO</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ozawa</LastName>
            <ForeName>Michael G</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Charville</LastName>
            <ForeName>Gregory W</ForeName>
            <Initials>GW</Initials>
            <Identifier Source="ORCID">0000-0002-2774-2704</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>KL2 TR003143</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>KL2TR003143</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>KL2TR003143</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Histopathology</MedlineTA>
        <NlmUniqueID>7704136</NlmUniqueID>
        <ISSNLinking>0309-0167</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071616">CDX2 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C491270">CDX2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006657">Histones</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071616" MajorTopicYN="N">CDX2 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018317" MajorTopicYN="Y">Nerve Sheath Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009442" MajorTopicYN="Y">Neurilemmoma</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="Y">Neurofibrosarcoma</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CDX2</Keyword>
        <Keyword MajorTopicYN="N">PRC2</Keyword>
        <Keyword MajorTopicYN="N">gene expression</Keyword>
        <Keyword MajorTopicYN="N">malignant peripheral nerve sheath tumour</Keyword>
        <Keyword MajorTopicYN="N">sarcoma</Keyword>
      </KeywordList>
      <CoiStatement><b>Declaration of conflicting interests</b>: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>51</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35122289</ArticleId>
        <ArticleId IdType="mid">NIHMS1804339</ArticleId>
        <ArticleId IdType="pmc">PMC9097546</ArticleId>
        <ArticleId IdType="doi">10.1111/his.14626</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>WHO Classification of Tumours Editorial Board, ed. WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours., 5th ed.
Lyon (France): International Agency for Research on Cancer, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Karamchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl. Immunohistochem. Mol. Morphol
2012; 20; 445–450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22495377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miettinen M, McCue PA, Sarlomo-Rikala M, et al.
Sox10 – A marker for not only Schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue. A systematic analysis of 5134 tumors. Am. J. Surg. Pathol
2015; 39; 826–835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4431945</ArticleId>
            <ArticleId IdType="pubmed">25724000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am. J. Surg. Pathol
2008; 32; 1291–1298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18636017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou H, Coffin CM, Perkins SL, Tripp SR, Liew M, Viskochil DH. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am. J. Surg. Pathol
2003; 27; 1337–1345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14508395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galatian AA, Crowson AN, Fischer RJ, Yob EH, Shendrik I. Malignant peripheral nerve sheath tumor with glandular differentiation in a patient with neurofibromatosis type 1. Am. J. Dermatopathol
2013; 35; 859–863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24247575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen WN, Strong EW, Bains MS, Woodruff JM. Neuroendocrine differentiation in the glandular peripheral nerve sheath tumor. Pathologic distinction from the biphasic synovial sarcoma with glands. Am. J. Surg. Pathol
1988; 12; 417–426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2837100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thway K, Hamarneh W, Miah AB, Fisher C. Malignant Peripheral Nerve Sheath Tumor With Rhabdomyosarcomatous and Glandular Elements: Rare Epithelial Differentiation in a Triton Tumor. Int. J. Surg. Pathol
2015; 23; 377–383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25911565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miki Y, Thway K. Malignant Peripheral Nerve Sheath Tumor With Divergent Glandular Differentiation. Int. J. Surg. Pathol
2017; 25; 310–313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28381143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodruff JM, Christensen WN. Glandular peripheral nerve sheath tumors. Cancer
1993; 72; 3618–3628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8252477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee W, Teckie S, Wiesner T, et al.
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet
2014; 46; 1227–1232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4249650</ArticleId>
            <ArticleId IdType="pubmed">25240281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Wang Y, Jones S, et al.
Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet
2014; 46; 1170–1172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4383254</ArticleId>
            <ArticleId IdType="pubmed">25305755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Murray B, Mo G, Shern JF. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor. Genes
2020; 11; 287.</Citation>
        </Reference>
        <Reference>
          <Citation>Cleven AHG, Sannaa GAA, Briaire-de Bruijn I, et al.
Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod. Pathol
2016; 29; 582–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4948583</ArticleId>
            <ArticleId IdType="pubmed">26990975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR. Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. Am. J. Surg. Pathol
2016; 40; 479–489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4882106</ArticleId>
            <ArticleId IdType="pubmed">26645727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaefer I-M, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod. Pathol
2016; 29; 4–13.</Citation>
        </Reference>
        <Reference>
          <Citation>Le Guellec S, Macagno N, Velasco V, et al.
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod. Pathol
2017; 30; 1677–1687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28752843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pekmezci M, Cuevas-Ocampo AK, Perry A, Horvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod. Pathol
2017; 30; 1710–1719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28776579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asano N, Yoshida A, Ichikawa H, et al.
Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology
2017; 70; 385–393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27580378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kochat V, Raman AT, Landers SM, et al.
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol
2021; 142; 565–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34283254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pemov A, Li H, Presley W, Wallace MR, Miller DT. Genetics of human malignant peripheral nerve sheath tumors. Neuro-Oncol. Adv
2020; 2; i50–i61.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith TA, Machen SK, Fisher C, Goldblum JR. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am. J. Clin. Pathol
1999; 112; 641–648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10549251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaimaktchiev V, Terracciano L, Tornillo L, et al.
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod. Pathol
2004; 17; 1392–1399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15205684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF. Cdx2 Protein Expression in Normal and Malignant Human Tissues: An Immunohistochemical Survey Using Tissue Microarrays. Mod. Pathol
2003; 16; 913–919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13679455</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
